Palbociclib 125Mg Tab

DRUG2 trials

Sponsors

Royal Marsden NHS Foundation Trust, University of Michigan Rogel Cancer Center

Conditions

CYP3A4*22ER+ Breast CancerHER2-negative Breast Cancer

Phase 2

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

RecruitingNCT04985266

Royal Marsden NHS Foundation TrustER+ Breast Cancer, HER2-negative Breast Cancer

Start: 2022-03-30End: 2030-09-01Target: 1100Updated: 2024-12-05

Phase 4

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

WithdrawnNCT05691400

University of Michigan Rogel Cancer CenterCYP3A4*22

Start: 2024-03-31End: 2027-03-31Updated: 2024-02-02

Related Papers

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer

Cancer Communications2023-10-1425 citations

Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER)

Cancer Research2023-03-013 citations

Abstract P5-05-01: Personalized Cancer Monitoring (PCM): a novel ctDNA tool to detect molecular residual disease in patients with early-stage breast cancer

Cancer Research2023-03-012 citations